We found that patients with EGFR abnormalities had a faster disease progression, the probability of tumor cell invasion and metastasis was significantly higher in patients with EGFR abnormalities compared to those with normal EGFR, and there was a high overlap between EGFR mutations and apparent copy number abnormalities, suggesting that DNA copy number abnormalities of EGFR also occur in NSCLC patients with EGFR mutations and have a role in the development of malignant tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.